Cingulate Inc. Common Stock
$5.24
$0.09 (+1.75%)
$5.09Day Range$5.28
Key Statistics
Market Cap
$76.20M
Shares Outstanding
14.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Dec 8, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$5.11
Day High
$5.28
Day Low
$5.09
Volume
83.2K
VWAP
$5.20
Prev Close
$5.15
Transactions
--
Acc. Volume
--
About Cingulate Inc. Common Stock
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
PHARMACEUTICAL PREPARATIONSSIC 283414 employees1901 W. 47TH PLACE, KANSAS CITY, KS, 66205(913) 942-2300IPO Dec 8, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001862150
- Composite FIGI
- BBG012G40MY2
- Share Class FIGI
- BBG012G40NT6
- Ticker Root
- CING
- SIC Code
- 2834
About Cingulate Inc. Common Stock (CING) Stock
Cingulate Inc. Common Stock (CING) closed the 2026-09-18 session at $5.24, up 1.75% versus the previous close (+0.09). The stock opened at $5.11 and traded between $5.09 and $5.28 during that session. Session trading volume was 83K shares. The volume-weighted average price (VWAP) is $5.20.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Cingulate Inc. Common Stock has a market capitalization of $76.2 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. CING is listed on the XNAS exchange. The company employs approximately 14 people. Cingulate Inc. Common Stock is headquartered in KANSAS CITY, KS. The recorded listing date is 2021-12-08.
On this page you can find market CING stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.